SG11202007530XA - Co-crystal forms of a novobiocin analog and proline - Google Patents
Co-crystal forms of a novobiocin analog and prolineInfo
- Publication number
- SG11202007530XA SG11202007530XA SG11202007530XA SG11202007530XA SG11202007530XA SG 11202007530X A SG11202007530X A SG 11202007530XA SG 11202007530X A SG11202007530X A SG 11202007530XA SG 11202007530X A SG11202007530X A SG 11202007530XA SG 11202007530X A SG11202007530X A SG 11202007530XA
- Authority
- SG
- Singapore
- Prior art keywords
- proline
- crystal forms
- novobiocin analog
- novobiocin
- analog
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627570P | 2018-02-07 | 2018-02-07 | |
| PCT/US2019/016304 WO2019156907A1 (en) | 2018-02-07 | 2019-02-01 | Co-crystal forms of a novobiocin analog and proline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007530XA true SG11202007530XA (en) | 2020-09-29 |
Family
ID=65444361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007530XA SG11202007530XA (en) | 2018-02-07 | 2019-02-01 | Co-crystal forms of a novobiocin analog and proline |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10717755B2 (https=) |
| EP (1) | EP3749675B1 (https=) |
| JP (3) | JP2021512910A (https=) |
| KR (2) | KR102718111B1 (https=) |
| CN (2) | CN118894894A (https=) |
| AR (1) | AR114245A1 (https=) |
| AU (3) | AU2019217821B2 (https=) |
| BR (1) | BR112020016205A2 (https=) |
| CA (2) | CA3226385A1 (https=) |
| CL (2) | CL2020002051A1 (https=) |
| CO (1) | CO2020009761A2 (https=) |
| EA (1) | EA202091885A1 (https=) |
| IL (2) | IL276583B2 (https=) |
| MX (2) | MX2020008326A (https=) |
| MY (1) | MY209803A (https=) |
| PE (1) | PE20211446A1 (https=) |
| SG (1) | SG11202007530XA (https=) |
| TW (2) | TWI868593B (https=) |
| WO (1) | WO2019156907A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL276583B2 (en) | 2018-02-07 | 2025-03-01 | Reata Pharmaceuticals Inc | Crystal structures of proline and a novobiocin analog |
| CN119264211A (zh) | 2018-08-27 | 2025-01-07 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| CN115181146B (zh) * | 2021-04-02 | 2024-06-04 | 浙江普洛家园药业有限公司 | 一种新生霉素的提取工艺 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013006651A2 (pt) * | 2010-09-23 | 2017-07-18 | Nuformix Ltd | composição e cocristal de aprepitante l-prolina |
| TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體 |
| CN108640910A (zh) * | 2011-11-25 | 2018-10-12 | 诺弗米克斯技术有限公司 | 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体 |
| EP2602249B1 (en) * | 2011-12-06 | 2015-08-12 | F.I.S. Fabbrica Italiana Sintetici S.p.A. | Synthesis of rosuvastatin by means of co-crystals |
| WO2013119985A1 (en) * | 2012-02-09 | 2013-08-15 | University Of Kansas | C-terminal hsp90 inhibitors |
| ES2671478T3 (es) * | 2012-08-31 | 2018-06-06 | Novartis Ag | Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales |
| TW201512201A (zh) * | 2013-03-14 | 2015-04-01 | Forum Pharmaceuticals Inc | 化合物的多晶型及鹽類 |
| CN106536498A (zh) * | 2014-06-24 | 2017-03-22 | 堪萨斯大学 | 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺 |
| HUE052588T2 (hu) * | 2014-09-30 | 2021-05-28 | Jiangsu Hengrui Medicine Co | Az L-prolin/nátrium-glukóz kotranszporter 2 gátló kristály komplexének kristálya |
| IL276583B2 (en) | 2018-02-07 | 2025-03-01 | Reata Pharmaceuticals Inc | Crystal structures of proline and a novobiocin analog |
-
2019
- 2019-02-01 IL IL276583A patent/IL276583B2/en unknown
- 2019-02-01 EP EP19705879.5A patent/EP3749675B1/en active Active
- 2019-02-01 SG SG11202007530XA patent/SG11202007530XA/en unknown
- 2019-02-01 TW TW112106332A patent/TWI868593B/zh active
- 2019-02-01 BR BR112020016205-1A patent/BR112020016205A2/pt unknown
- 2019-02-01 US US16/265,256 patent/US10717755B2/en active Active
- 2019-02-01 KR KR1020207025571A patent/KR102718111B1/ko active Active
- 2019-02-01 KR KR1020247033920A patent/KR20240155354A/ko not_active Ceased
- 2019-02-01 CA CA3226385A patent/CA3226385A1/en active Pending
- 2019-02-01 WO PCT/US2019/016304 patent/WO2019156907A1/en not_active Ceased
- 2019-02-01 MY MYPI2020004057A patent/MY209803A/en unknown
- 2019-02-01 EA EA202091885A patent/EA202091885A1/ru unknown
- 2019-02-01 CN CN202410935084.1A patent/CN118894894A/zh active Pending
- 2019-02-01 IL IL315865A patent/IL315865A/en unknown
- 2019-02-01 CN CN201980011980.6A patent/CN112020506B/zh active Active
- 2019-02-01 PE PE2020001199A patent/PE20211446A1/es unknown
- 2019-02-01 CA CA3090646A patent/CA3090646C/en active Active
- 2019-02-01 AU AU2019217821A patent/AU2019217821B2/en active Active
- 2019-02-01 MX MX2020008326A patent/MX2020008326A/es unknown
- 2019-02-01 TW TW108104336A patent/TWI797249B/zh active
- 2019-02-01 JP JP2020542665A patent/JP2021512910A/ja active Pending
- 2019-02-05 AR ARP190100277A patent/AR114245A1/es unknown
-
2020
- 2020-06-05 US US16/894,461 patent/US11401294B2/en active Active
- 2020-08-06 MX MX2022012856A patent/MX2022012856A/es unknown
- 2020-08-06 CO CONC2020/0009761A patent/CO2020009761A2/es unknown
- 2020-08-07 CL CL2020002051A patent/CL2020002051A1/es unknown
-
2022
- 2022-12-05 AU AU2022283638A patent/AU2022283638B2/en active Active
- 2022-12-27 CL CL2022003784A patent/CL2022003784A1/es unknown
-
2023
- 2023-02-13 US US18/168,495 patent/US20240043465A1/en not_active Abandoned
- 2023-10-05 JP JP2023173340A patent/JP2024001167A/ja not_active Withdrawn
-
2024
- 2024-10-25 AU AU2024227646A patent/AU2024227646A1/en active Pending
-
2025
- 2025-10-23 JP JP2025178611A patent/JP2026012851A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279468A (en) | Crystallographic modifications of odeviccibat | |
| IL277628A (en) | IMIDAZOPIPERAZINE inhibitors of proteins that activate transcription | |
| SG11202106378VA (en) | Modulators of hsd17b13 expression | |
| PT3833662T (pt) | Inibidores da interação proteína-proteína keap1-nrf2 | |
| SG11202102636UA (en) | Modulators of pnpla3 expression | |
| EP3849559A4 (en) | COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF | |
| IL276583A (en) | Crystal structures of proline and a novobiocin analog | |
| GB201707644D0 (en) | Display crate and kit of parts therefor | |
| GB2565433B (en) | Reconciliation of run-time and configuration discrepancies | |
| EP3664904A4 (en) | ANALOGUE STICK HEIGHT EXTENSION | |
| EP3415635B8 (en) | Age determination of a human individual | |
| HUE062956T2 (hu) | Eljárások niraparib és köztitermékei elõállítására | |
| EP3843630A4 (en) | ANALYSIS OF SYMMETRY OF LIMB FUNCTION | |
| PT3199824T (pt) | Sistema de fixação e utilização de um sistema de fixação | |
| ZA202105399B (en) | Use of spiropidion | |
| ZA202100587B (en) | Peptide compounds and therapeutic uses of same | |
| SG11202107366QA (en) | Actuation of execution units | |
| PL3684370T3 (pl) | Kompozycja i leczenie zaniku geograficznego fludrokortyzonem | |
| HK40043253A (en) | Co-crystal forms of a novobiocin analog and proline | |
| PL3759108T3 (pl) | Mimetyki poliproliny pochodnego proliny modułu-15 | |
| IL269364B (en) | A process for the large-scale production of tricyclic aminoglycosides and their intermediates | |
| IL282566A (en) | Synthesis of (S)-6-hydroxytryptophan and their derivatives | |
| ZA202104656B (en) | Deuterated forms and derivatives of volinanserin | |
| SG11202011378WA (en) | Synthesis of tipifarnib | |
| GB201802060D0 (en) | Sampling of microorganisms |